2-[(1H-1,2,3-triazol-5-yl)sulfanyl]acetic acid | 141956-65-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-[(1H-1,2,3-triazol-5-yl)sulfanyl]acetic acid
• 英文别名: (3H-[1,2,3]Triazol-4-ylsulfanyl)-acetic acid；2-((1H-1,2,3-Triazol-5-yl)thio)acetic acid；2-(2H-triazol-4-ylsulfanyl)acetic acid
• CAS: 141956-65-2
• 化学式: C₄H₅N₃O₂S
• mdl: MFCD20641726
• 分子量: 159.169
• InChiKey: MTSXLTRWDHXAIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(1H-1,2,3-triazol-5-yl)sulfanyl]acetic acid 、 4-(三氟甲氧基)苯甲胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 以43%的产率得到2-[(1H-1,2,3-triazol-5-yl)sulfanyl]-N-[4-(trifluoromethoxy)benzyl]acetamide
  参考文献：
  名称：

  硫代乙酰胺-三唑类抗大肠杆菌的合成及构效关系

  摘要：

  由于多重耐药菌株的传播，革兰氏阴性菌引起的感染越来越危险，强调迫切需要具有替代作用模式的新抗生素。我们之前使用抗叶酸靶向筛选确定了一类新型抗菌剂硫代乙酰胺-三唑，并确定了它们的作用方式，这取决于半胱氨酸合酶 A 的激活。在此，我们报告了对抗 E 的详细检查。硫代乙酰胺-三唑的大肠杆菌构效关系。合成了初始命中化合物的类似物，以研究芳基、硫代乙酰胺和三唑部分的贡献。观察到明确的结构-活性关系产生具有优异抑制值的化合物。对芳环的取代通常是最好的耐受性，包括引入噻唑和吡啶杂芳基系统。对中央硫代乙酰胺接头部分的替换更为细微；将甲基支链引入硫代乙酰胺接头显着降低了抗菌活性，但异构丙酰胺和 N-苯甲酰胺系统保留了活性。分子中三唑部分的变化显着降低了抗菌活性，进一步表明 1,2,3-三唑对效力至关重要。从这些研究中，我们确定了具有理想的体外 ADME 特性和体内药代动力学特性的新先导化合物。将甲基支链引入

  DOI：

  10.3390/molecules27051518
• 作为产物：
  描述：

  (3H-[1,2,3]Triazol-4-ylsulfanyl)-acetic acid methyl ester 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 以100%的产率得到2-[(1H-1,2,3-triazol-5-yl)sulfanyl]acetic acid
  参考文献：
  名称：

  Rationally designed "dipeptoid" analogs of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist (CI-988)

  摘要：

  This paper outlines the synthesis of selected acid mimics of the non-peptide CCK-B selective antagonist CI-988, 1. CCK-B and CCK-A binding affinities of these analogues are described and their CCK-B affinity and selectivity rationalized by consideration of the pK(a) values, charge distribution, and geometry of the respective acid mimics. Several of the compounds have CCK-B binding affinities similar to the parent carboxylic acid 1 (CCK-B, IC50 = 1.7 nM; pK(a) = 5.6) and span a pK(a) range of <1 (sulfonic acid 27) to >9.5 (5-thio-1,2,4-triazole 24). Among the more active compounds synthesized are tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[2-[[2-[[(3-hydroxy-5-isoxazolyl)acetyl]-amino]-2-phenylethyl]amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl]carbamate (15), tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[2-[(1-oxo-3-sulfopropyl)amino]-2-phenylethyl]amino]-ethyl]carbamate, monosodium salt (27), and tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[2-1[(1H-1,2,4-triazol-5-ylsulfinyl)acetyl]amino]-2-phenylethyl]amino]ethyl]carbamic acid (34) which have CCK-B binding affinities of IC50 = 2.6,1.3, and 1.7 nM, CCK-A/-B ratios of 650,780, and 550 and pK(a) values of 6.5, <1, and 7.0, respectively.

  DOI：

  10.1021/jm00092a007

文献信息

• Inhibitors of protein tyrosine phosphatase
  申请人：Pharmacia & Upjohn Company

  公开号：US06353023B1

  公开（公告）日：2002-03-05

  The present invention comprises small molecular weight, non-peptidic inhibitors of formula I and II of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).

  本发明涉及小分子量、非肽类的蛋白酪氨酸磷酸酶1（PTP1）的化学式I和II的抑制剂，用于治疗和/或预防非胰岛素依赖型糖尿病（NIDDM）。
• Modification of the N-terminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: identification of analogues with cellular activity
  作者：Scott D. Larsen、F.Craig Stevens、Thomas J. Lindberg、Paul M. Bodnar、Theresa J. O'Sullivan、Heinrich J. Schostarez、Barbara J. Palazuk、John E. Bleasdale

  DOI：10.1016/s0960-894x(02)01065-x

  日期：2003.3

  Low molecular weight peptidomimetic compounds based on 0-malonyl tyrosine and 0-carboxymethyl salicylic acid are potent inhibitors of PTP1B. Modifications of the N-terminal Boc-Phe moiety were undertaken in an effort to improve physical chemical properties and to achieve cellular activity. Although Phe ultimately proved to be the optimal N-terminal amino acid, several viable replacements for the Boc group were identified, two of which afforded analogues that were effective at enhancing the insulin-stimulated uptake of 2-deoxyglucose by L6 myocytes. (C) 2003 Elsevier Science Ltd. All rights reserved.
• Synthesis and Structure–Activity Relationship of Thioacetamide-Triazoles against Escherichia coli
  作者：Suresh Dharuman、Miranda J. Wallace、Stephanie M. Reeve、Jürgen B. Bulitta、Richard E. Lee

  DOI：10.3390/molecules27051518

  日期：——

  were more nuanced; the introduction of a methyl branch to the thioacetamide linker substantially decreased antibacterial activity, but the isomeric propionamide and N-benzamide systems retained activity. Changes to the triazole portion of the molecule dramatically decreased the antibacterial activity, further indicating that 1,2,3-triazole is critical for potency. From these studies, we have identified

  由于多重耐药菌株的传播，革兰氏阴性菌引起的感染越来越危险，强调迫切需要具有替代作用模式的新抗生素。我们之前使用抗叶酸靶向筛选确定了一类新型抗菌剂硫代乙酰胺-三唑，并确定了它们的作用方式，这取决于半胱氨酸合酶 A 的激活。在此，我们报告了对抗 E 的详细检查。硫代乙酰胺-三唑的大肠杆菌构效关系。合成了初始命中化合物的类似物，以研究芳基、硫代乙酰胺和三唑部分的贡献。观察到明确的结构-活性关系产生具有优异抑制值的化合物。对芳环的取代通常是最好的耐受性，包括引入噻唑和吡啶杂芳基系统。对中央硫代乙酰胺接头部分的替换更为细微；将甲基支链引入硫代乙酰胺接头显着降低了抗菌活性，但异构丙酰胺和 N-苯甲酰胺系统保留了活性。分子中三唑部分的变化显着降低了抗菌活性，进一步表明 1,2,3-三唑对效力至关重要。从这些研究中，我们确定了具有理想的体外 ADME 特性和体内药代动力学特性的新先导化合物。将甲基支链引入
• Rationally designed "dipeptoid" analogs of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist (CI-988)
  作者：Martin J. Drysdale、Martyn C. Pritchard、David C. Horwell

  DOI：10.1021/jm00092a007

  日期：1992.7

  This paper outlines the synthesis of selected acid mimics of the non-peptide CCK-B selective antagonist CI-988, 1. CCK-B and CCK-A binding affinities of these analogues are described and their CCK-B affinity and selectivity rationalized by consideration of the pK(a) values, charge distribution, and geometry of the respective acid mimics. Several of the compounds have CCK-B binding affinities similar to the parent carboxylic acid 1 (CCK-B, IC50 = 1.7 nM; pK(a) = 5.6) and span a pK(a) range of <1 (sulfonic acid 27) to >9.5 (5-thio-1,2,4-triazole 24). Among the more active compounds synthesized are tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[2-[[2-[[(3-hydroxy-5-isoxazolyl)acetyl]-amino]-2-phenylethyl]amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl]carbamate (15), tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[2-[(1-oxo-3-sulfopropyl)amino]-2-phenylethyl]amino]-ethyl]carbamate, monosodium salt (27), and tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[2-1[(1H-1,2,4-triazol-5-ylsulfinyl)acetyl]amino]-2-phenylethyl]amino]ethyl]carbamic acid (34) which have CCK-B binding affinities of IC50 = 2.6,1.3, and 1.7 nM, CCK-A/-B ratios of 650,780, and 550 and pK(a) values of 6.5, <1, and 7.0, respectively.